サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1659475

組換えDNA技術の世界市場

Recombinant DNA Technology

出版日
ページ情報
英文 88 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
組換えDNA技術の世界市場
出版日: 2025年02月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 88 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

組換えDNA技術の世界市場は2030年までに1,041億米ドルに到達

2024年に800億米ドルと推定される組換えDNA技術の世界市場は、2024年から2030年にかけてCAGR 4.5％で成長し、2030年には1,041億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである医療組換えDNA技術は、CAGR 5.0％を記録し、分析期間終了時には779億米ドルに達すると予測されます。非医療用組換えDNA技術分野の成長率は、分析期間中CAGR 3.1％と推定されます。

米国市場は215億米ドル、中国はCAGR 4.2％で成長予測

米国の組換えDNA技術市場は、2024年に215億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに165億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは4.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.1%と3.7%と予測されています。欧州では、ドイツがCAGR約3.3％で成長すると予測されています。

組換えDNA技術：主要動向と促進要因のまとめ

組換えDNA技術とは何か、なぜ現代バイオテクノロジーの要なのか？

組換えDNA技術は単に遺伝子工学と呼ばれることもあるが、異なる生物のDNAを組み合わせて、所望の形質や機能を持つ新しい遺伝子の組み合わせを作り出すことを含みます。これは、宿主生物のDNAに特定の遺伝子を挿入することによって達成され、自然には生じないような新しいタンパク質の発現や新しい機能の実行を可能にします。酵素を使ってDNAを特定の部位で切断し、他の酵素を使ってそれらを新しいゲノムに「接着」させることで、科学者はさまざまな用途に合わせた組み換えDNA分子を作り出すことができます。この技術は、遺伝子の正確な操作を可能にし、新規タンパク質の生産、生物工学的薬剤の合成、農作物の回復力の強化につながるため、生物学、医学、農業、工業に変革をもたらしました。

組換えDNA技術は、インスリン、成長ホルモン、抗体といった価値の高い物質を、細胞を利用して大量に生産することを可能にするため、バイオテクノロジーの基礎となります。組換えDNA技術以前は、糖尿病用のインスリンなどの重要な治療薬は、限られた高価な量の動物組織から採取されていました。今日、細菌中の組み換えDNAによって生産された生物工学的インスリンは、より安全で効果的であり、世界中で入手可能です。高度に特異的なタンパク質やホルモンを生産するこの能力は、ヘルスケアの治療成績を向上させただけでなく、研究や診断の進歩も支えており、組換えDNA技術は現代分子生物学の礎石となっています。

組換えDNA技術は医療や農業にどのように応用されていますか？

医療分野では、組換えDNA技術はワクチン、治療用タンパク質、遺伝子治療の生産に変革をもたらしました。最もよく知られている応用例の一つは、ヒトインスリンの生産です。組換えDNA技術によって、ヒトインスリン遺伝子が細菌のプラスミドに挿入され、細菌がヒトの体内で自然に生成されるインスリンと生物学的に同一のインスリンを生成できるようになりました。この進歩により、安定したスケーラブルなインスリン供給源が可能となり、糖尿病治療に革命をもたらしました。同様に、B型肝炎のような病気のワクチンは組換えDNAを用いて製造されます。この場合、ウイルスの遺伝物質の一部のみが発現されるため、ウイルス粒子全体を使用する従来のワクチンに伴うリスクが排除されます。遺伝子組換え技術はまた、患者の細胞に機能的遺伝子を導入することで、欠陥のある遺伝子の置換や修復を行う遺伝子治療もサポートしており、嚢胞性線維症、血友病、ある種のがんなどの遺伝性疾患の治療に有望視されています。

農業分野では、組換えDNA技術によって、害虫や病気、干ばつや高塩分といった環境ストレスに強い遺伝子組み換え作物の開発が可能になった。例えば、Btトウモロコシは特定の昆虫に有毒な細菌タンパク質を発現する遺伝子組み換え作物で、化学農薬の必要性を減らし、より持続可能な農業システムを促進します。さらに、発展途上国におけるビタミンA欠乏症と闘うために、ビタミンAの前駆体であるベータカロチンを生成するように遺伝子組み換えされたゴールデンライスのように、栄養価を向上させるために遺伝子組み換えされた作物もあります。組換えDNA技術は、作物の収量や品質を向上させるだけでなく、世界の食料安全保障や持続可能な農業に貢献する、幅広い農業改良を可能にしました。

組換えDNA技術を取り巻く倫理的、規制的配慮とは？

組換えDNA技術は多大な利益をもたらす一方で、倫理的・規制的な議論も巻き起こしています。農業における遺伝子組み換え作物（GMO）が環境や健康に与える影響について、しばしば懸念が生じる。例えば、遺伝子組み換え作物が野生植物と交雑する可能性は、除草剤耐性形質の拡散など、生態系への予期せぬ影響に対する懸念を引き起こします。批評家たちは、遺伝子組み換え作物は生物多様性を減少させ、生態系に予期せぬ結果をもたらす可能性があると主張します。一方、擁護派は、食糧不足に対処し、農薬の使用を減らすことで農業が環境に与える影響を最小限に抑えるという遺伝子組み換え作物の役割を強調しています。米国のFDA、USDA、EPAのような規制機関や、世界中の同様の機関が遺伝子組み換え作物の安全性を監督し、遺伝子組み換え作物が消費に安全で、環境にリスクをもたらさないことを保証しています。

医療においては、組換えDNA技術は、特に遺伝子治療とヒトにおける遺伝子組み換えをめぐる倫理的問題を提起しています。遺伝子治療は遺伝性疾患の治療に有望である一方、「デザイナーベビー」や治療目的を超えた遺伝子組み換えの可能性についての懸念も生じています。このため、遺伝子編集・治療研究においては、悪用を防止し、遺伝子介入が責任を持って行われるよう、厳格なガイドラインや倫理基準が設けられています。組換えDNA技術から得られる遺伝情報は、個人や家族に関するセンシティブな情報を明らかにする可能性があるため、プライバシーと同意はさらに倫理的な考慮事項です。米国国立衛生研究所（NIH）や世界保健機関（WHO）が提供するガイドラインのような規制の枠組みは、組換えDNAの応用を監督する上で重要な役割を果たしており、技術革新と安全性および倫理的完全性のバランスをとっています。

組換えDNA技術市場の成長の原動力は？

組換えDNA技術市場の成長は、遺伝子研究の進歩、個別化医療に対する需要の増加、農業やバイオ製造における技術革新によってもたらされます。CRISPR-Cas9遺伝子編集システムを含む技術の進歩は、遺伝子操作に革命をもたらし、従来の組み換えDNA技術よりも正確で効率的な編集を可能にしました。こうした進歩は、正確なDNA操作が不可欠な遺伝子治療や遺伝子研究への応用を加速させています。個人の遺伝子プロファイルに合わせた治療を行う個別化医療の台頭は、市場の成長をさらに後押ししています。組換えDNA技術は、モノクローナル抗体や細胞療法など、特に腫瘍学や希少遺伝性疾患において、疾患の遺伝的基盤に対処するように設計された標的治療を生み出す鍵となります。

農業では、持続可能な食糧生産と気候変動への耐性の必要性の高まりにより、遺伝子組み換え作物への依存度が高まっています。組換えDNA技術は、干ばつや高温などの過酷な条件に耐える作物の開発を可能にし、気候変動の影響を受ける地域の食糧安全保障を支えます。さらに、バイオ製造-組換えDNA技術を使ってバイオベースの材料やバイオ燃料を生産する-は、持続可能な製造における主要なアプリケーションとして台頭してきています。世界がバイオエコノミーに移行するにつれて、医薬品、繊維、化学品などの産業におけるバイオ製造製品の需要は伸び、組換えDNA技術市場をさらに促進すると予想されます。これらの動向を総合すると、組換えDNA技術がバイオテクノロジーにおけるイノベーションの推進役として、医療、農業、持続可能な産業全体の進歩を支える役割を担っていることが浮き彫りになります。

セグメント

製品タイプ（医療、非医療）、タイプ（発現システム、クローニングベクター）、アプリケーション（健康・疾病、食品・農業、環境、その他アプリケーション）

調査対象企業の例（注目の32社）

  • Amgen Inc
  • Bamboo Therapeutics, Inc.
  • Biocon
  • Biogen
  • Chiron Corporation
  • Cibus
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc
  • GenScript
  • GlaxoSmithKline plc.
  • Horizon Discovery Group plc
  • Merck KGaA
  • Monsanto Company
  • New England Biolabs
  • Novartis AG
  • Novo Nordisk A/S
  • Nucelis
  • Pfizer Inc.
  • Profacgen
  • Sanofi
  • Syngene

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP22688

Global Recombinant DNA Technology Market to Reach US$104.1 Billion by 2030

The global market for Recombinant DNA Technology estimated at US$80.0 Billion in the year 2024, is expected to reach US$104.1 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Medical Recombinant DNA Technology, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$77.9 Billion by the end of the analysis period. Growth in the Non-Medical Recombinant DNA Technology segment is estimated at 3.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$21.5 Billion While China is Forecast to Grow at 4.2% CAGR

The Recombinant DNA Technology market in the U.S. is estimated at US$21.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$16.5 Billion by the year 2030 trailing a CAGR of 4.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.1% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Recombinant DNA Technology: Key Trends & Drivers Summarized

What Is Recombinant DNA Technology and Why Is It a Cornerstone of Modern Biotechnology?

Recombinant DNA technology, often simply called genetic engineering, involves combining DNA from different organisms to create new genetic combinations with desired traits or functions. This is achieved by inserting specific genes into the DNA of host organisms, allowing them to express new proteins or perform new functions that would not naturally occur. By using enzymes to cut DNA at specific sites and other enzymes to “glue” them into a new genome, scientists can create recombinant DNA molecules tailored for various applications. This technology has had a transformative impact on biology, medicine, agriculture, and industry, as it allows for the precise manipulation of genes, leading to the production of novel proteins, the synthesis of bioengineered drugs, and the enhancement of crop resilience.

Recombinant DNA technology is foundational to biotechnology because it enables the production of substances with high value, such as insulin, growth hormones, and antibodies, by harnessing cells to produce them in large quantities. Before recombinant DNA technology, critical medical treatments, such as insulin for diabetes, were harvested from animal tissues in limited and costly quantities. Today, bioengineered insulin produced through recombinant DNA in bacteria is safer, more effective, and available worldwide. This ability to produce highly specific proteins and hormones has not only improved treatment outcomes in healthcare but has also supported advancements in research and diagnostics, making recombinant DNA technology a cornerstone of modern molecular biology.

How Is Recombinant DNA Technology Applied in Medicine and Agriculture?

In medicine, recombinant DNA technology has transformed the production of vaccines, therapeutic proteins, and gene therapy. One of the most well-known applications is the production of human insulin. Through recombinant DNA technology, human insulin genes are inserted into bacterial plasmids, allowing bacteria to produce insulin that is biologically identical to that naturally produced in the human body. This advancement has enabled a stable and scalable source of insulin, revolutionizing diabetes treatment. Similarly, vaccines for diseases like hepatitis B are produced using recombinant DNA, where only part of the virus’s genetic material is expressed, eliminating risks associated with traditional vaccines that use whole virus particles. Recombinant technology also supports gene therapy, where defective genes are replaced or repaired by introducing functional genes into a patient’s cells, showing promise for treating genetic disorders such as cystic fibrosis, hemophilia, and certain forms of cancer.

In agriculture, recombinant DNA technology has enabled the development of genetically modified crops that are more resilient to pests, diseases, and environmental stressors like drought or high salinity. For instance, Bt corn is a genetically modified crop that expresses a bacterial protein toxic to certain insects, reducing the need for chemical pesticides and promoting a more sustainable agricultural system. Additionally, crops have been modified to improve nutritional content, such as Golden Rice, which has been engineered to produce beta-carotene, a precursor to vitamin A, to combat vitamin A deficiency in developing countries. Recombinant DNA technology has enabled a wide array of agricultural enhancements that not only improve crop yield and quality but also contribute to global food security and sustainable farming practices.

What Are the Ethical and Regulatory Considerations Surrounding Recombinant DNA Technology?

While recombinant DNA technology has brought tremendous benefits, it has also sparked ethical and regulatory debates. Concerns often arise around the environmental and health impacts of genetically modified organisms (GMOs) in agriculture. For instance, the potential for GMOs to crossbreed with wild plants raises concerns about unintended ecological effects, such as the spread of herbicide-resistant traits. Critics argue that genetically modified crops could reduce biodiversity and lead to unintended consequences in ecosystems. On the other hand, advocates emphasize the role of GMOs in addressing food scarcity and minimizing the environmental impact of farming through reduced pesticide use. Regulatory bodies like the FDA, USDA, and EPA in the United States, as well as similar agencies worldwide, oversee GMO safety to ensure that genetically modified crops are safe for consumption and do not pose risks to the environment.

In medicine, recombinant DNA technology raises ethical questions, particularly around gene therapy and genetic modification in humans. While gene therapy holds promise for treating genetic diseases, it also raises concerns about “designer babies” and the potential for genetic modifications that go beyond therapeutic purposes. This has led to the establishment of strict guidelines and ethical standards in gene editing and therapy research to prevent misuse and ensure that genetic interventions are performed responsibly. Privacy and consent are additional ethical considerations, as genetic information derived from recombinant DNA techniques can reveal sensitive information about individuals or families. Regulatory frameworks, such as the guidelines provided by the National Institutes of Health (NIH) and the World Health Organization (WHO), play a critical role in overseeing recombinant DNA applications, balancing innovation with safety and ethical integrity.

What Is Driving Growth in the Recombinant DNA Technology Market?

The growth in the recombinant DNA technology market is driven by advancements in genetic research, increasing demand for personalized medicine, and innovations in agriculture and biomanufacturing. Technological advancements, including the CRISPR-Cas9 gene-editing system, have revolutionized gene manipulation, allowing for more precise and efficient editing than traditional recombinant DNA techniques. These advancements have accelerated applications in gene therapy and genetic research, where precise DNA manipulation is essential. The rise of personalized medicine, which tailors treatments to individual genetic profiles, further supports market growth. Recombinant DNA technology is key to producing targeted treatments, such as monoclonal antibodies and cell therapies, that are designed to address the genetic basis of diseases, particularly in oncology and rare genetic disorders.

In agriculture, the growing need for sustainable food production and resilience to climate change is increasing reliance on genetically modified crops. Recombinant DNA technology enables the development of crops that can withstand extreme conditions, such as drought or high temperatures, supporting food security in regions impacted by climate change. Additionally, bio-manufacturing—using recombinant DNA technology to produce bio-based materials and biofuels—is emerging as a major application in sustainable manufacturing. As the world transitions to a bioeconomy, demand for biomanufactured products in industries like pharmaceuticals, textiles, and chemicals is expected to grow, further propelling the recombinant DNA technology market. Collectively, these trends highlight the role of recombinant DNA technology as a driver of innovation in biotechnology, supporting advancements across medicine, agriculture, and sustainable industry.

SCOPE OF STUDY:

The report analyzes the Recombinant DNA Technology market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Medical, Non-Medical); Type (Expression System, Cloning Vector); Application (Health & Disease, Food & Agriculture, Environmental, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

  • Amgen Inc
  • Bamboo Therapeutics, Inc.
  • Biocon
  • Biogen
  • Chiron Corporation
  • Cibus
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc
  • GenScript
  • GlaxoSmithKline plc.
  • Horizon Discovery Group plc
  • Merck KGaA
  • Monsanto Company
  • New England Biolabs
  • Novartis AG
  • Novo Nordisk A/S
  • Nucelis
  • Pfizer Inc.
  • Profacgen
  • Sanofi
  • Syngene

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Recombinant DNA Technology - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Demand for Biopharmaceuticals Drives Growth in Recombinant DNA Technology for Drug Development
    • Expansion of Gene Therapy and Personalized Medicine Spurs Adoption of Recombinant DNA Techniques
    • Advancements in Genetic Engineering Propel Innovation in Recombinant DNA Technology Applications
    • Rising Prevalence of Chronic Diseases Boosts Demand for Recombinant DNA-Based Therapeutics
    • Growing Focus on Vaccine Development Expands Market for Recombinant DNA Technology in the Biotech Industry
    • Increasing Demand for Genetically Modified Organisms (GMOs) in Agriculture Spurs Use of Recombinant DNA Techniques
    • Advances in CRISPR and Gene Editing Tools Enhance Precision and Efficiency in Recombinant DNA Applications
    • Growing Adoption of Recombinant Proteins in Diagnostics Expands Use Cases for Recombinant DNA Technology
    • Expansion of Biopharmaceutical Manufacturing Drives Demand for Recombinant DNA in Protein Production
    • Increasing Research in Rare Disease Treatments Fuels Development of Recombinant DNA-Based Therapies
    • Rising Awareness of Synthetic Biology Creates Opportunities for Recombinant DNA in Industrial Biotechnology
    • Growing Focus on Cell and Gene Therapy Research Expands Applications for Recombinant DNA Technology
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recombinant DNA Technology Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Recombinant DNA Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Recombinant DNA Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Recombinant DNA Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Medical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Medical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Medical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Non-Medical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Non-Medical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Non-Medical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Expression System by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Expression System by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Expression System by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Cloning Vector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Cloning Vector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Cloning Vector by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Health & Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Health & Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Health & Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Food & Agriculture by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Food & Agriculture by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Food & Agriculture by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Environmental by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Environmental by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Environmental by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Recombinant DNA Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Recombinant DNA Technology by Product Type - Medical and Non-Medical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Recombinant DNA Technology by Product Type - Medical and Non-Medical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Recombinant DNA Technology by Product Type - Percentage Breakdown of Value Sales for Medical and Non-Medical for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Recombinant DNA Technology by Type - Expression System and Cloning Vector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Recombinant DNA Technology by Type - Expression System and Cloning Vector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Recombinant DNA Technology by Type - Percentage Breakdown of Value Sales for Expression System and Cloning Vector for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Recombinant DNA Technology by Application - Health & Disease, Food & Agriculture, Environmental and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Recombinant DNA Technology by Application - Health & Disease, Food & Agriculture, Environmental and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Recombinant DNA Technology by Application - Percentage Breakdown of Value Sales for Health & Disease, Food & Agriculture, Environmental and Other Applications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Recombinant DNA Technology by Product Type - Medical and Non-Medical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Recombinant DNA Technology by Product Type - Medical and Non-Medical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Recombinant DNA Technology by Product Type - Percentage Breakdown of Value Sales for Medical and Non-Medical for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Recombinant DNA Technology by Type - Expression System and Cloning Vector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Recombinant DNA Technology by Type - Expression System and Cloning Vector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Recombinant DNA Technology by Type - Percentage Breakdown of Value Sales for Expression System and Cloning Vector for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Recombinant DNA Technology by Application - Health & Disease, Food & Agriculture, Environmental and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Recombinant DNA Technology by Application - Health & Disease, Food & Agriculture, Environmental and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Recombinant DNA Technology by Application - Percentage Breakdown of Value Sales for Health & Disease, Food & Agriculture, Environmental and Other Applications for the Years 2015, 2025 & 2030
  • JAPAN
    • Recombinant DNA Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Recombinant DNA Technology by Product Type - Medical and Non-Medical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Recombinant DNA Technology by Product Type - Medical and Non-Medical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Recombinant DNA Technology by Product Type - Percentage Breakdown of Value Sales for Medical and Non-Medical for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Recombinant DNA Technology by Type - Expression System and Cloning Vector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Recombinant DNA Technology by Type - Expression System and Cloning Vector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Recombinant DNA Technology by Type - Percentage Breakdown of Value Sales for Expression System and Cloning Vector for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Recombinant DNA Technology by Application - Health & Disease, Food & Agriculture, Environmental and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Recombinant DNA Technology by Application - Health & Disease, Food & Agriculture, Environmental and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Recombinant DNA Technology by Application - Percentage Breakdown of Value Sales for Health & Disease, Food & Agriculture, Environmental and Other Applications for the Years 2015, 2025 & 2030
  • CHINA
    • Recombinant DNA Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Recombinant DNA Technology by Product Type - Medical and Non-Medical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Recombinant DNA Technology by Product Type - Medical and Non-Medical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Recombinant DNA Technology by Product Type - Percentage Breakdown of Value Sales for Medical and Non-Medical for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Recombinant DNA Technology by Type - Expression System and Cloning Vector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Recombinant DNA Technology by Type - Expression System and Cloning Vector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Recombinant DNA Technology by Type - Percentage Breakdown of Value Sales for Expression System and Cloning Vector for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Recombinant DNA Technology by Application - Health & Disease, Food & Agriculture, Environmental and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Recombinant DNA Technology by Application - Health & Disease, Food & Agriculture, Environmental and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Recombinant DNA Technology by Application - Percentage Breakdown of Value Sales for Health & Disease, Food & Agriculture, Environmental and Other Applications for the Years 2015, 2025 & 2030
  • EUROPE
    • Recombinant DNA Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Recombinant DNA Technology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Recombinant DNA Technology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Recombinant DNA Technology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Recombinant DNA Technology by Product Type - Medical and Non-Medical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Recombinant DNA Technology by Product Type - Medical and Non-Medical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Recombinant DNA Technology by Product Type - Percentage Breakdown of Value Sales for Medical and Non-Medical for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Recombinant DNA Technology by Type - Expression System and Cloning Vector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Recombinant DNA Technology by Type - Expression System and Cloning Vector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Recombinant DNA Technology by Type - Percentage Breakdown of Value Sales for Expression System and Cloning Vector for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Recombinant DNA Technology by Application - Health & Disease, Food & Agriculture, Environmental and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Recombinant DNA Technology by Application - Health & Disease, Food & Agriculture, Environmental and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Recombinant DNA Technology by Application - Percentage Breakdown of Value Sales for Health & Disease, Food & Agriculture, Environmental and Other Applications for the Years 2015, 2025 & 2030
  • FRANCE
    • Recombinant DNA Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Recombinant DNA Technology by Product Type - Medical and Non-Medical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Recombinant DNA Technology by Product Type - Medical and Non-Medical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Recombinant DNA Technology by Product Type - Percentage Breakdown of Value Sales for Medical and Non-Medical for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Recombinant DNA Technology by Type - Expression System and Cloning Vector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Recombinant DNA Technology by Type - Expression System and Cloning Vector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Recombinant DNA Technology by Type - Percentage Breakdown of Value Sales for Expression System and Cloning Vector for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Recombinant DNA Technology by Application - Health & Disease, Food & Agriculture, Environmental and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Recombinant DNA Technology by Application - Health & Disease, Food & Agriculture, Environmental and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Recombinant DNA Technology by Application - Percentage Breakdown of Value Sales for Health & Disease, Food & Agriculture, Environmental and Other Applications for the Years 2015, 2025 & 2030
  • GERMANY
    • Recombinant DNA Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Recombinant DNA Technology by Product Type - Medical and Non-Medical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Recombinant DNA Technology by Product Type - Medical and Non-Medical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Recombinant DNA Technology by Product Type - Percentage Breakdown of Value Sales for Medical and Non-Medical for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Recombinant DNA Technology by Type - Expression System and Cloning Vector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Recombinant DNA Technology by Type - Expression System and Cloning Vector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Recombinant DNA Technology by Type - Percentage Breakdown of Value Sales for Expression System and Cloning Vector for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Recombinant DNA Technology by Application - Health & Disease, Food & Agriculture, Environmental and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Recombinant DNA Technology by Application - Health & Disease, Food & Agriculture, Environmental and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Recombinant DNA Technology by Application - Percentage Breakdown of Value Sales for Health & Disease, Food & Agriculture, Environmental and Other Applications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Recombinant DNA Technology by Product Type - Medical and Non-Medical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Recombinant DNA Technology by Product Type - Medical and Non-Medical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Recombinant DNA Technology by Product Type - Percentage Breakdown of Value Sales for Medical and Non-Medical for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Recombinant DNA Technology by Type - Expression System and Cloning Vector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Recombinant DNA Technology by Type - Expression System and Cloning Vector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Recombinant DNA Technology by Type - Percentage Breakdown of Value Sales for Expression System and Cloning Vector for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Recombinant DNA Technology by Application - Health & Disease, Food & Agriculture, Environmental and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Recombinant DNA Technology by Application - Health & Disease, Food & Agriculture, Environmental and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Recombinant DNA Technology by Application - Percentage Breakdown of Value Sales for Health & Disease, Food & Agriculture, Environmental and Other Applications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Recombinant DNA Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Recombinant DNA Technology by Product Type - Medical and Non-Medical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Recombinant DNA Technology by Product Type - Medical and Non-Medical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Recombinant DNA Technology by Product Type - Percentage Breakdown of Value Sales for Medical and Non-Medical for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Recombinant DNA Technology by Type - Expression System and Cloning Vector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Recombinant DNA Technology by Type - Expression System and Cloning Vector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Recombinant DNA Technology by Type - Percentage Breakdown of Value Sales for Expression System and Cloning Vector for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Recombinant DNA Technology by Application - Health & Disease, Food & Agriculture, Environmental and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Recombinant DNA Technology by Application - Health & Disease, Food & Agriculture, Environmental and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Recombinant DNA Technology by Application - Percentage Breakdown of Value Sales for Health & Disease, Food & Agriculture, Environmental and Other Applications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for Recombinant DNA Technology by Product Type - Medical and Non-Medical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Rest of Europe Historic Review for Recombinant DNA Technology by Product Type - Medical and Non-Medical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Rest of Europe 15-Year Perspective for Recombinant DNA Technology by Product Type - Percentage Breakdown of Value Sales for Medical and Non-Medical for the Years 2015, 2025 & 2030
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Recombinant DNA Technology by Type - Expression System and Cloning Vector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for Recombinant DNA Technology by Type - Expression System and Cloning Vector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Rest of Europe 15-Year Perspective for Recombinant DNA Technology by Type - Percentage Breakdown of Value Sales for Expression System and Cloning Vector for the Years 2015, 2025 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Recombinant DNA Technology by Application - Health & Disease, Food & Agriculture, Environmental and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Recombinant DNA Technology by Application - Health & Disease, Food & Agriculture, Environmental and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Rest of Europe 15-Year Perspective for Recombinant DNA Technology by Application - Percentage Breakdown of Value Sales for Health & Disease, Food & Agriculture, Environmental and Other Applications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Recombinant DNA Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Recombinant DNA Technology by Product Type - Medical and Non-Medical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific Historic Review for Recombinant DNA Technology by Product Type - Medical and Non-Medical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Asia-Pacific 15-Year Perspective for Recombinant DNA Technology by Product Type - Percentage Breakdown of Value Sales for Medical and Non-Medical for the Years 2015, 2025 & 2030
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Recombinant DNA Technology by Type - Expression System and Cloning Vector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for Recombinant DNA Technology by Type - Expression System and Cloning Vector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Asia-Pacific 15-Year Perspective for Recombinant DNA Technology by Type - Percentage Breakdown of Value Sales for Expression System and Cloning Vector for the Years 2015, 2025 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Recombinant DNA Technology by Application - Health & Disease, Food & Agriculture, Environmental and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Recombinant DNA Technology by Application - Health & Disease, Food & Agriculture, Environmental and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Asia-Pacific 15-Year Perspective for Recombinant DNA Technology by Application - Percentage Breakdown of Value Sales for Health & Disease, Food & Agriculture, Environmental and Other Applications for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 131: Rest of World Recent Past, Current & Future Analysis for Recombinant DNA Technology by Product Type - Medical and Non-Medical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of World Historic Review for Recombinant DNA Technology by Product Type - Medical and Non-Medical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of World 15-Year Perspective for Recombinant DNA Technology by Product Type - Percentage Breakdown of Value Sales for Medical and Non-Medical for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Recombinant DNA Technology by Type - Expression System and Cloning Vector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for Recombinant DNA Technology by Type - Expression System and Cloning Vector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of World 15-Year Perspective for Recombinant DNA Technology by Type - Percentage Breakdown of Value Sales for Expression System and Cloning Vector for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Recombinant DNA Technology by Application - Health & Disease, Food & Agriculture, Environmental and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Recombinant DNA Technology by Application - Health & Disease, Food & Agriculture, Environmental and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of World 15-Year Perspective for Recombinant DNA Technology by Application - Percentage Breakdown of Value Sales for Health & Disease, Food & Agriculture, Environmental and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION